[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368261-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368261-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","clinicopathological-characterisation-of-mtap-alterations-in-gastrointestinal-cancers","Clinicopathological characterisation of MTAP alterations in gastrointestinal cancers","","Methylthioadenosine phosphorylase (MTAP) loss is an alteration within the purine and methionine salvage pathway that may create a selective dependency on related metabolic targets. This study evaluates prevalence, clinicopathological characteristics, and prognosis of MTAP alterations in gastrointestinal cancers using TCGA cases and a real-world next-generation sequencing cohort. Gene loss was the most frequent alteration, mainly co-occurring with CDKN2A/B loss and enriched in biliopancreatic and gastro-oesophageal cancers. MTAP loss showed no worse prognosis.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/clinicopathological-characterisation-of-mtap-alterations-in-gastrointestinal-cancers/368261/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/clinicopathological-characterisation-of-mtap-alterations-in-gastrointestinal-cancers/368261.png","ImageObject",300,407,{"name":42,"@type":43},"Oliver","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-21","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is MTAP, and why is MTAP loss relevant in cancer?","Question",{"text":63,"@type":64},"MTAP is an essential metabolic enzyme in the purine and methionine salvage pathway. In cancer, MTAP loss can create a selective dependency on related pathways, making it potentially actionable.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were MTAP alterations identified in this study?",{"text":68,"@type":64},"MTAP alterations were retrieved from The Cancer Genome Atlas (TCGA) and from a real-world gastrointestinal cancer cohort profiled by next-generation sequencing. If alterations other than loss were found, immunohistochemistry was performed.",{"name":70,"@type":61,"acceptedAnswer":71},"Does MTAP loss worsen prognosis in gastrointestinal cancers?",{"text":72,"@type":64},"No. The study reports that MTAP loss did not confer worse prognosis despite its presence in a subset of gastrointestinal cancers.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368261,1790205610,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":107,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Original research  \nClinicopathological characterisation of MTAP alterations in gastrointestinal cancers  \nGianluca Mauri  , 1,2,3 Giorgio Patelli, 1,2,3 Laura Roazzi,2,3 Emanuele Valtorta,4 Alessio Amatu,3 Giovanna Marrapese,3 Erica Bonazzina,3 Federica Tosi,3  \nKatia Bencardino,3 Gabriele Ciarlo,2,3 Elisa Mariella, 1,5 Silvia Marsoni, 1  \nAlberto Bardelli, 1,5 Emanuela Bonoldi,4 Andrea Sartore-Bianchi,2,3,6 Salvatore Siena2,3  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.1136/jcp-2023-209341](10.1136/jcp-2023-209341)) .  \n1IFOM ETS – The AIRC Institute of Molecular Oncology, Milan, Italy  \n2Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy 3Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy  \n4Department of Pathology, Grande Ospedale Metropolitano Niguarda, Milan, Italy 5Department of Oncology, Molecular Biotechnology Center, University of Torino, Turin, Italy 6Division of Research and Innovation, Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy  \nCorrespondence to  \nDr Gianluca Mauri; gianluca. [mauri@unimi.it](mauri@unimi.it)  \nGM, GP and LR contributed equally.  \nGM, GP and LR are joint first authors.  \nAS-B and SS are joint senior authors.  \nReceived 9 December 2023 Accepted 3 January 2024  \n© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ Group.  \nTo cite: Mauri G, Patelli G, Roazzi L, et al. J Clin Pathol Epub ahead of print: [please include Day Month Year] . doi:10 . 1136/jcp-2023- 209341  \nABSTRACT  \nBackground Methylthioadenosine phosphorylase (MTAP) is an essential metabolic enzyme in the  \npurine and methionine salvage pathway. In cancer, MTAP gene copy number loss (MTAP loss) confers a selective dependency on the related protein arginine methyltransferase 5. The impact of MTAP alterations in gastrointestinal (GI) cancers remains unknown although hypothetically druggable. Here, we aim to investigate the prevalence, clinicopathological features and prognosis of MTAP loss GI cancers.  \nMethods Cases with MTAP alterations were retrieved from The Cancer Genome Atlas (TCGA) and a realworld cohort of GI cancers profiled by next-generation sequencing. If MTAP alterations other than loss were found, immunohistochemistry was performed. Finally, we set a case–control study to assess MTAP loss prognostic impact.  \nResults Findings across the TCGA dataset (N=1363 patients) and our cohort (N=508) were consistent. Gene loss was the most common MTAP alteration (9 .4%), mostly co-occurring with CDKN2A/B loss (97 . 7%) . Biliopancreatic and gastro-oesophageal cancers had the highest prevalence of MTAP loss (20 . 5% and 12. 7%, respectively), being mostly microsatellite stable (99 . 2%) . In colorectal cancer, MTAP loss was rare (1 . 1%), while most MTAP alterations were mutations (5/7, 71.4%); among the latter, only MTAP-CDKN2B truncation led to protein loss, thus potentially actionable. MTAP loss did not confer worse prognosis.  \nConclusions MTAP alterations are found in 5%–10% of GI cancers, most frequently biliopancreatic and gastrooesophageal. MTAP loss is the most common alteration, identified almost exclusively in MSS, CDKN2A/B loss, upper-GI cancers. Other MTAP alterations were found in colorectal cancer, but unlikely to cause protein loss and drug susceptibility.  \nINTRODUCTION  \nThe mechanism of action of most targeted anticancer therapies is essentially the inhibition of oncogenic stimuli through tyrosine-kinase receptor blockade.1–3 However, oncogene-addicted cancers eventually develop resistance under drug-induced selective pressure, limiting targeted therapy efficacy.4 Thus, alternative or complementary therapeutic approaches are warranted.  \nAntimetabolic targeted therapies are emerging as new strategies to in","cbCaim4jPSH0zHdf","https://ap.wps.com/l/cbCaim4jPSH0zHdf","pdf",933661,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n# What is already known on this topic\n# What this study adds\n# How this study might affect research, practice or policy","[{\"question\":\"What is MTAP, and why is MTAP loss relevant in cancer?\",\"answer\":\"MTAP is an essential metabolic enzyme in the purine and methionine salvage pathway. In cancer, MTAP loss can create a selective dependency on related pathways, making it potentially actionable.\"},{\"question\":\"How were MTAP alterations identified in this study?\",\"answer\":\"MTAP alterations were retrieved from The Cancer Genome Atlas (TCGA) and from a real-world gastrointestinal cancer cohort profiled by next-generation sequencing. If alterations other than loss were found, immunohistochemistry was performed.\"},{\"question\":\"Does MTAP loss worsen prognosis in gastrointestinal cancers?\",\"answer\":\"No. The study reports that MTAP loss did not confer worse prognosis despite its presence in a subset of gastrointestinal cancers.\"}]","Clinicopathological characterisation of MTAP alterations in gastrointestinal cancers | PDF",1790175905,18,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e59db4b6dc93d6e4a73ef72ebfefc63.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/80ae64e4711782c5d5501dd4a2655589.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/55939407d98a3bb76cb4b6a02545b160.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4f7294eab5b0e24bf0eb1c0bebfa76a2.webp",980,1306]